Asthma as a Type I Hypersensitivity Reaction and Laboratory Diagnosis: A Review of Current Literature

Vol 8 No 6 (2025): Volume 08 Issue 06 June 2025

Article Date Published : 21 June 2025 | Page No.: 2987-2994 | Google Scholar | Crossref doi for this article

Abstract :

Asthma is a common chronic respiratory disease affecting people worldwide. Globally, over 260 million people were estimated to have asthma in 2019, with an incidence peak in children aged 5–9 years. Prevalence tends to be higher in high-income countries (~6–8%) than in low- and middle-income countries (~2–5%). In Nigeria, national surveys find that 2.5% of people report doctor-diagnosed asthma, while 6.4% have “clinical asthma” (symptoms suggestive of asthma) and 9.0% report wheezing in the past year. Rates rise with age: e.g. 10–17-year-olds have clinical asthma in ~3–10%. In Southeast Nigeria (Enugu State), school-based studies similarly show high prevalence: one recent survey found overall bronchial asthma in ~11.3% of children, with urban pupils (13.1%) slightly more affected than rural (11.2%). Asthma is an IgE‐mediated type I hypersensitivity reaction characterized by an initial sensitization to inhaled allergens, followed by allergen challenge that triggers mast cell and basophil degranulation, resulting in bronchoconstriction, mucus hypersecretion, and airway inflammation. Understanding asthma immunopathology is essential for precision therapy. Therefore, a central objective is to precisely phenotype patients so that appropriate biologics can be selected. Standardized biomarkers are critical for this. For instance, serum total and specific IgE (or skin prick) assess atopy, blood eosinophil count and sputum eosinophils measure airway eosinophilia, and FeNO reflects IL-13–driven inflammation. International guidelines endorse such testing: NICE and ATS recommend FeNO for asthma diagnosis and monitoring, and ERS/ATS guidelines highlight sputum eosinophil counts and FeNO to guide therapy in severe casest. In practice, an elevated FeNO (>50 ppb) or blood eosinophils (≥150–300 cells/µL) suggests Type-2-high asthma responsive to steroids and biologics. Indeed, sputum-guided management (treating to maintain eosinophils <3%) reduces exacerbations, although its use is currently limited to specialty centres.

Keywords :

Asthma, chronic respiratory disease, FeNO, IgE-mediated, IL-13, Type I hypersensitivity, Type-2-high asthma

References :

  1. Abbas, M., Moussa, M., Akel, H. (2023). Type I Hypersensitivity Reaction. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32809396.
  2. Adiele, D.K., Onyia, J.T., Oguonu, T., & Obionu, C.N. (2022). Epidemiology and severity of bronchial asthma among school-aged children in EnuguState, south-east, nigeria. Nigerian Journal of Paediatrics, 49(4), 311–317.
  3. Barne, M. (2023). Gaps in asthma diagnosis and treatment in low- and middle-income countries. Frontiers in Allergy, 4, 1240259. https://doi.org/10.3389/falgy.2023.1240259
  4. Bousquet, J., Heinzerling, L., Bachert, C., Papadopoulos, N. G., Bousquet, P. J., Burney, P. G., Canonica, G. W., Carlsen, K. H., Cox, L., Haahtela, T., Lodrup Carlsen, K. C., Price, D., Samolinski, B., Simons, F. E., Wickman, M., Annesi-Maesano, I., Baena-Cagnani, C. E., Bergmann, K. C., Bindslev-Jensen, C., Casale, T. B., Allergic Rhinitis and its Impact on Asthma (2012). Practical guide to skin prick tests in allergy to aeroallergens. Allergy, 67(1), 18–24. https://doi.org/10.1111/j.1398-9995.2011.02728.x
  5. Cao, Y., Chen, S., Chen, X., Zou, W., Liu, Z., Wu, Y., & Hu, S. (2022). Global trends in the incidence and mortality of asthma from 1990 to 2019: An age-period-cohort analysis using the global burden of disease study 2019. Frontiers in public health, 10, 1036674. https://doi.org/10.3389/fpubh.2022.1036674
  6. Chung, K.F., Wenzel, S.E., Brozek, J.L., Bush, A., Castro, M., Sterk, P.J., Adcock, I.M., Bateman, E.D., Bel, E.H., Bleecker, E.R., Boulet, L.P., Brightling, C., Chanez, P., Dahlen, S.E., Djukanovic, R., Frey, U., Gaga, M., Gibson, P., Hamid, Q., Jajour, N.N., Teague, W.G. (2014). International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. The European Respiratory Journal, 43(2), 343–373. https://doi.org/10.1183/09031936.00202013
  7. Dweik, R. A., Boggs, P. B., Erzurum, S. C., Irvin, C. G., Leigh, M. W., Lundberg, J. O., Olin, A. C., Plummer, A. L., Taylor, D. R., & American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications (2011). An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. American Journal of Respiratory and Critical Care Medicine, 184(5), 602–615. https://doi.org/10.1164/rccm.9120-11ST
  8. Feng, Y., Xu, L., Zhang, J., Bin, J., Pang, X., He, S., & Fang, L. (2024). Allergenic protein-induced type I hypersensitivity models: a review. Frontiers in allergy, 5, 1481011. https://doi.org/10.3389/falgy.2024.1481011
  9. Froidure, A., Mouthuy, J., Durham, S.R., Chanez, P., Sibille, Y., & Pilette, C. (2016). Asthma phenotypes and IgE responses. The European respiratory journal, 47(1), 304–319. https://doi.org/10.1183/13993003.01824-2014
  10. GBD 2019 Risk Factors Collaborators (2020). Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England), 396(10258), 1223–1249. https://doi.org/10.1016/S0140-6736(20)30752-2
  11. GINA committee. (2023). Global strategy for asthma management and prevention 2023 update. Global Initiative for Asthma: Fontana, WI, USA.
  12. Johansson, S.G. (2004). ImmunoCAP Specific IgE test: an objective tool for research and routine allergy diagnosis. Expert review of molecular diagnostics, 4(3), 273–279. https://doi.org/10.1586/14737159.4.3.273
  13. Keshavarz, B., Platts-Mills, T. A. E., & Wilson, J. M. (2021). The use of microarray and other multiplex technologies in the diagnosis of allergy. Annals of Allergy, Asthma & Immunology : official publication of the American College of Allergy, Asthma, & Immunology, 127(1), 10–18. https://doi.org/10.1016/j.anai.2021.01.003
  14. Kim, T.H., Kim, H., Oh, J., Kim, S., Miligkos, M., Yon, D.K., & Papadopoulos, N.G. (2025). Global burden of asthma among children and adolescents with projections to 2050: a comprehensive review and forecasted modeling study. Clinical and Experimental Pediatrics, 68(5), 329–343. https://doi.org/10.3345/cep.2025.00423
  15. Lopes, F.D.T.Q.S., Tibério, I.F.L.C., Leme, A., & Fairclough, L. (2022). Editorial: The importance of Th17/Treg imbalance in asthma and COPD development and progression. Frontiers in Immunology, 13, 1025215. https://doi.org/10.3389/fimmu.2022.1025215
  16. Luo, W., Hu, J., Xu, W., & Dong, J. (2022). Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma. Frontiers in Immunology, 13, 974066. https://doi.org/10.3389/fimmu.2022.974066
  17. Matsuda, M., Shimizu, S., Kitatani, K., & Nabe, T. (2022). Extracellular Vesicles Derived from Allergen Immunotherapy-Treated Mice Suppressed IL-5 Production from Group 2 Innate Lymphoid Cells. Pathogens (Basel, Switzerland), 11(11), 1373. https://doi.org/10.3390/pathogens11111373
  18. Meghji, J., Mortimer, K., Agusti, A., Allwood, B.W., Asher, I., Bateman, E. D., Bissell, K., Bolton, C.E., Bush, A., Celli, B., Chiang, C.Y., Cruz, A.A., Dinh-Xuan, A.T., El Sony, A., Fong, K.M., Fujiwara, P.I., Gaga, M., Garcia-Marcos, L., Halpin, D.M.G., Hurst, J.R., Marks, G.B. (2021). Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet (London, England), 397(10277), 928–940. https://doi.org/10.1016/S0140-6736(21)00458-X
  19. Menzies-Gow, A., Mansur, A.H., & Brightling, C.E. (2020). Clinical utility of fractional exhaled nitric oxide in severe asthma management. The European respiratory journal, 55(3), 1901633. https://doi.org/10.1183/13993003.01633-2019
  20. Michel, M., Klingebiel, C., & Vitte, J. (2023). Tryptase in type I hypersensitivity. Annals of Allergy, Asthma & Immunology: official publication of the American College of Allergy, Asthma, & Immunology, 130(2), 169–177. https://doi.org/10.1016/j.anai.2022.08.996
  21. Murugesan, N., Saxena, D., Dileep, A., Adrish, M., & Hanania, N. A. (2023). Update on the Role of FeNO in Asthma Management. Diagnostics (Basel, Switzerland), 13(8), 1428. https://doi.org/10.3390/diagnostics13081428
  22. (2024). Asthma: Diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN). National Institute for Health and Care Excellence (NICE).
  23. Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., Zeyneloglu, C., Giannelli Viscardi, O., Ardicli, O., Kiykim, A., Garcia-Sanchez, A., Lopez, J., Shi, L., Yang, M., Schneider, S., . . . Akdis, C. (2025). Type 2 immunity in allergic diseases. Cellular and Molecular Immunology, 22(3), 211–242. 10.1038/s41423-025-01261-2
  24. Ozoh, O.B., Aderibigbe, S.A., Ayuk, A.C., Desalu, O.O., Oridota, O.E., Olufemi, O., Egbagbe, E., Babashani, M., Shopeyin, A., Ukwaja, K., & Dede, S.K. (2019). The prevalence of asthma and allergic rhinitis in Nigeria: A nationwide survey among children, adolescents and adults. PloS one, 14(9), e0222281. https://doi.org/10.1371/journal.pone.0222281
  25. Peri, F., Amaddeo, A., Badina, L., Maschio, M., Barbi, E., & Ghirardo, S. (2023). T2-Low Asthma: A Discussed but Still Orphan Disease. Biomedicines, 11(4), 1226. https://doi.org/10.3390/biomedicines11041226
  26. Rabe, A.P.J., Loke, W.J., Gurjar, K., Brackley, A., & Lucero-Prisno Iii, D.E. (2023). Global Burden of Asthma, and Its Impact on Specific Subgroups: Nasal Polyps, Allergic Rhinitis, Severe Asthma, Eosinophilic Asthma. Journal of Asthma and Allergy, 16, 1097–1113. https://doi.org/10.2147/JAA.S418145
  27. Robinson, D., Humbert, M., Buhl, R., Cruz, A. A., Inoue, H., Korom, S., Hanania, N. A., & Nair, P. (2017). Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 47(2), 161–175. https://doi.org/10.1111/cea.12880
  28. Shamji, M.H., Valenta, R., Jardetzky, T., Verhasselt, V., Durham, S.R., Würtzen, P.A., & van Neerven, R.J.J. (2021). The role of allergen-specific IgE, IgG and IgA in allergic disease. Allergy, 76(12), 3627–3641. https://doi.org/10.1111/all.14908
  29. Simpson, A.J., & Price, O.J. (2023). NICE asthma guidelines: time to re-evaluate the diagnostic value of exercise challenge testing?. ERJ Open Research, 9(2), 00447-2022. https://doi.org/10.1183/23120541.00447-2022
  30. Sinyor, B., & Concepcion, P.L. (2023). Pathophysiology Of Asthma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551579/
  31. Strip, I. S. I. C., & Anti-IgE, I. S. I. (2025). ImmunoCAP® specific IgE.
  32. Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., & Abdelalim, A. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the global burden of disease study 2019. The Lancet, 396(10258), 1204–1222.
  33. Vroman, H., Hendriks, R. W., & Kool, M. (2017). Dendritic Cell Subsets in Asthma: Impaired Tolerance or Exaggerated Inflammation?. Frontiers in Immunology, 8, 941. https://doi.org/10.3389/fimmu.2017.00941

How to Cite :

Asthma as a Type I Hypersensitivity Reaction and Laboratory Diagnosis: A Review of Current Literature. Erhunmwunse RU, Duru EE, Ehiaghe FA, Ogbodo EC, 8(6), 2987-2994. Retrieved from https://ijcsrr.org/single-view/?id=23057&pid=22781

Most read articles by the same author(s)

Erhunmwunse RU, Duru EE, Ehiaghe FA, Ogbodo EC,

View

164

Citation

Downloads

Article Details